Renasys recall

Quote
If you are so unhappy #52, please have the balls to let us know who you are. Since you are announcing life is too tough and you are leaving, it shouldnt matter if we know who you are. You are the epitome of a douche canoe....
 












Text book example of "air your dirty laundry in public."

Come on people this is not real and all fabricated.

Everything is still a go and that is a fake letter. Check snopes.com
 






Anonymous said:
Text book example of "air your dirty laundry in public."

Come on people this is not real and all fabricated.

Everything is still a go and that is a fake letter. Check snopes.com
Click to expand...

Yeah, because two people sitting in their basement running a website don't believe this letter is real. I don't know if it's a recall, but I got a letter from a hospital and it matches this one, and I don't work for you.
 






I am a newbie at S&N and the rumors are bogus. I have not heard a thing in the field. I just got a PO and I just sold 45 Renasys pumps. You people are silly.

The rumors are from scared competitors.

Smith and Nephew is #1.
 






Anonymous said:
I am a newbie at S&N and the rumors are bogus. I have not heard a thing in the field. I just got a PO and I just sold 45 Renasys pumps. You people are silly.

The rumors are from scared competitors.

Smith and Nephew is #1.
Click to expand...

I am a customer and I GOT the letter so if you haven't heard a thing it is most likely because you have your head so far up your ass that all you can hear here is bowel sounds. Idiots, POS company, POS product.
 












Smith & Nephew SN.LN -0.47% PLC has missed out on the bouquet again. Shares in the London-listed, Dublin-based maker of replacement joints dipped around 2% in morning trading Monday, after U.S. pacemaker specialist Medtronic Inc.MDT -1.12%said it was buying Smith & Nephew’s Dublin-based rival Covidien COV +16.98%PLC for $42.9 billion.

That removes a potential suitor for Smith & Nephew, which as a small player in a consolidating market has long been touted as a takeover target. Shares in the artificial joint maker have risen more than 20% this year on rumors of takeover interest, and with Medtronic out of the picture, the field has narrowed.

Still, Medtronic wasn’t the only eligible match. Stryker Corp.SYK +1.40%—another U.S. artificial-joint manufacturer—said last month it was in the preliminary stages of evaluating a deal for Smith & Nephew but didn’t intend to make a formal offer. Under U.K. takeover rules, Stryker is now prevented from making a bid until November, but can return sooner if a rival bidder emerges.

A number of companies that were looking at a deal to buy S&N rival Biomet Inc., whichZimmer Holdings Inc.ZMH -0.57% bought in April, are now reviewing other opportunities in the sector, said one senior health-care banker.

The Medtronic deal highlights Smith & Nephew’s possible tax advantages. Smith & Nephew’s U.K. listing could make it attractive for a U.S. firm looking to use cash trapped offshore, and to pursue a so-called inversion deal to relocate in a country with a more favorable corporate tax rate, as Medtronic is doing.

The top 10 U.S. medical-technology firms are sitting on around $63 billion in cash and short-term investments, much of which is likely offshore, Berenberg estimates.

The attractiveness of inversion deals has risen after the European Union said it was investigating ways in which U.S. firms use practices like transfer pricing—another way companies can sidestep high U.S. corporate taxes—to lower their tax burden.

Still, Smith & Nephew’s own 28.9% tax rate shows that such a move may be tricky for a buyer to achieve. And at 20 times next year’s forecast earnings, around a 33% premium to its orthopedic peers, its shares are still pricing in a lot of interest.

“SN’s premium valuation is currently supported by M&A,” Morgan Stanley analyst Michael Jungling said in a note to clients Monday, noting that it is rare for Smith & Nephew to trade at a premium to peers on a sustainable basis. Its investors still hear wedding bells ahead.
 






























Who told you that 2 weeks was the magic number?

What makes you think they will start letting people go? This isnt KCI, we have other things to sell while this gets sorted out.
 












Anonymous said:
Device is a piece of shit and our customers are going back to KCI anyway.
We should stick to dressings and drop Npwt all together
Click to expand...

It is called the dinosaur effect. Company big body but pea size brain. You know it is a bad product when our product manager suddenly gives up and runs the other direction away from the device. To bad corporate can not see it.

I also call it, "putting lipstick on the pig."
 




































Top Bottom
Back
Quote